JNJ-55920839 / J&J - LARVOL DELTA

Novel signatures associated with systemic lupus erythematosus clinical response to IFN-α/-ω inhibition. (PubMed, Lupus) - "These signatures may enable enrichment for treatment responders when using IFN-I-suppressing treatments in SLE."

Clinical • Journal • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Pharmacokinetics and Pharmacodynamics of JNJ-55920839, an Antibody Targeting Interferon α/ω, in Healthy Subjects and Subjects with Mild-to-Moderate Systemic Lupus Erythematosus. (PubMed, Clin Drug Investig) - P1 | "Pharmacokinetic and pharmacodynamic analyses of the data from this study demonstrated that there was biphasic disposition in both healthy subjects and subjects with SLE, CL was faster in subjects with SLE, and increases in total IFNα/ω levels were observed in both healthy subjects and subjects with SLE after treatment with JNJ-55920839, thus further development is supported. The study is registered at ClinicalTrials.gov NCT02609789."

Clinical • Journal • PK/PD data • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus